Literature DB >> 20536718

Cerebral oedema in minimal hepatic encephalopathy due to extrahepatic portal venous obstruction.

Amit Goel1, Santosh Yadav, Vivek Saraswat, Arti Srivastava, M Albert Thomas, Chandra M Pandey, Ramkishore Rathore, Rakesh Gupta.   

Abstract

BACKGROUND: Minimal hepatic encephalopathy (MHE) has recently been reported in patients with extrahepatic portal venous obstruction (EHPVO). AIMS: To evaluate brain changes by magnetic resonance studies in EHPVO patients.
METHODS: Blood ammonia level, critical flicker frequency (CFF), brain metabolites on 1H-magnetic resonance (MR) spectroscopy and brain water content on diffusion tensor imaging and magnetization transfer ratio (MTR) were studied in 31 EHPVO patients with and without MHE, as determined by neuropsychological tests. CFF and magnetic resonance imaging studies were also performed in 23 controls.
RESULTS: Fourteen patients (14/31, 45%) had MHE. Blood ammonia level was elevated in all, being significantly higher in the MHE than no MHE group. CFF was abnormal in 13% (4/31) with EHPVO and in 21% (3/14) with MHE. On 1H-MR spectroscopy, increased Glx/Cr, decreased mIns/Cr, and no change in Cho/Cr were noted in patients with MHE compared with controls. Significantly increased mean diffusivity (MD) and decreased (MTR) were observed in the MHE group, suggesting presence of interstitial cerebral oedema (ICE). MD correlated positively with blood ammonia level (r=0.65, P=0.003) and Glx (r=0.60, P=0.003). DISCUSSION: MHE was detected in 45% of patients with EHPVO while CFF was abnormal in only 13%. ICE was present in 7/10 brain regions examined, particularly in those with MHE. Hyperammonaemia elevated cerebral Glx levels correlated well with ICE.
CONCLUSIONS: MHE was common in EHPVO; CFF could identify it only in a minority. ICE was present in EHPVO, particularly in those with MHE. It correlated with blood ammonia and Glx/Cr levels. Hyperammonaemia seems to contribute to ICE in EHPVO.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20536718     DOI: 10.1111/j.1478-3231.2010.02289.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  Abnormal spontaneous brain activity in minimal hepatic encephalopathy: resting-state fMRI study.

Authors:  Wei-Jia Zhong; Zhi-Ming Zhou; Jian-Nong Zhao; Wei Wu; Da-Jing Guo
Journal:  Diagn Interv Radiol       Date:  2016 Mar-Apr       Impact factor: 2.630

Review 2.  Hepatology in India and INASL: A Ringside View.

Authors:  Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2012-09-21

3.  Minimal hepatic encephalopathy in children with liver cirrhosis: diffusion-weighted MR imaging and proton MR spectroscopy of the brain.

Authors:  Ahmed Abdel Khalek Abdel Razek; Ahmed Abdalla; Amany Ezzat; Ahmed Megahed; Tarek Barakat
Journal:  Neuroradiology       Date:  2014-07-25       Impact factor: 2.804

4.  Globus pallidus MR signal abnormalities in children with chronic liver disease and/or porto-systemic shunting.

Authors:  Sylviane Hanquinet; Claire Morice; Delphine S Courvoisier; Vladimir Cousin; Mehrak Anooshiravani; Laura Merlini; Valérie A McLin
Journal:  Eur Radiol       Date:  2017-04-06       Impact factor: 5.315

5.  Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Saudi J Gastroenterol       Date:  2012 May-Jun       Impact factor: 2.485

6.  Meta-analysis: The diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy.

Authors:  F J Torlot; M J W McPhail; S D Taylor-Robinson
Journal:  Aliment Pharmacol Ther       Date:  2013-01-07       Impact factor: 8.171

7.  Structural and functional abnormalities of default mode network in minimal hepatic encephalopathy: a study combining DTI and fMRI.

Authors:  Rongfeng Qi; Qiang Xu; Long Jiang Zhang; Jianhui Zhong; Gang Zheng; Shengyong Wu; Zhiqiang Zhang; Wei Liao; Yuan Zhong; Ling Ni; Qing Jiao; Zongjun Zhang; Yijun Liu; Guangming Lu
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.